At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
ALN-TTR02 (patisiran) administered by intravenous (IV) infusiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02
In Brief
A Phase 2 clinical trial evaluating ALN-TTR02 (patisiran) administered by intravenous (IV) infusion for TTR-mediated Amyloidosis. Completed, enrolled 27 participants across 9 sites in 7 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and tolerability of long-term dosing with ALN-TTR02 (patisiran) in patients with transthyretin (TTR) mediated amyloidosis (ATTR).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTTR-mediated Amyloidosis
CountriesBrazil, France, Germany, Portugal, Spain, Sweden, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedOct 2013
Primary CompletionJul 2016
Study CompletionAug 2016
TodayJul 2026
First PostedOct 14, 2013
Enrollment StartOct 1, 2013
Primary CompletionJul 1, 2016
Study CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.7 years ago
Interventions
ALN-TTR02 (patisiran) administered by intravenous (IV) infusiondrug